Toxic Epidermal Necrolysis (TEN) in a Patient with Human Immunodeficiency Virus: Case Report

Article Sidebar

PDF
Published: Mar 1, 2025
DOI: https://doi.org/10.47191/ijmscrs/v5-i03-02
Keywords:
SSJ/TEN drug reaction systemic dermatoses HIV dermatosis in hiv

Main Article Content

Edgar Nahim Acosta Carreón
Internal Medicine Department, Fourth Year Internal Medicine Resident. Hospital General de Cancún Dr. Jesús Kumate Rodríguez, SESA. Faculty of Medicine, UADY, Autonomous University of Yucatan.
Brian Artemio Perez Canul
Internal Medicine Department, Ninth-Semester Medical Student. Hospital General de Chetumal, SESA. Faculty of Medicine, UAEQROO, Autonomous University of the State of Quintana Roo.

Abstract

Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) is a spectrum of mucocutaneous hypersensitivity reactions. This report details the case of an18-year-old male patient with a history of HIV who developed extensive skin lesions and mucosal involvement after using carbamazepine. The diagnosis was confirmed clinically, and it was treated with intravenous corticosteroids, crystalloid solutions, supportive care, and discontinuation of the implicated drug, resulting in favorable clinical evolution. This case highlights the importance of early recognition of SJS/TEN and immediate withdrawal of the causative agent to improve prognosis.

Article Details

How to Cite
Acosta Carreón, E. N. ., & Brian Artemio Perez Canul. (2025). Toxic Epidermal Necrolysis (TEN) in a Patient with Human Immunodeficiency Virus: Case Report. International Journal of Medical Science and Clinical Research Studies, 5(3), 414–418. https://doi.org/10.47191/ijmscrs/v5-i03-02
Issue
Vol. 5 No. 3 (2025): Volume 05 Issue 03 March 2025
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Callahan SW, Oza VS. Stevens-Johnson Syndrome—A Look Back. JAMA Dermatol. 2017; 153(2):240. DOI:10.1001/jamadermatol.2016.0180

II. Hama N, Aoki S, Chen CB, et. al. Recent progress in Stevens-Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. Br J Dermatol. 2025; 192(4):9-18.

DOI: 10.1093/bjd/ljae321.

III. Ergen EN, Hughey LC. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatol. 2017; 153(12):1344.

DOI:10.1001/jamadermatol.2017.3957

IV. Shah H, Parisi R, Mukherjee E. et al. Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. Am J Clin Dermatol. 2024; 25:891-908.

DOI: https://doi.org/10.1007/s40257-024-00889-6

V. Arenas R. Dermatología. Atlas, diagnóstico y tratamiento. 8a ed. México: Mc Graw Hill, 2024.

VI. Álvarez MA, Bastidas AM, Lino CH, Guanotasig KD. Síndrome de necrólisis epidérmica tóxica y síndrome de Stevens Johnson. Clínica y Tratamiento. Pol Con. 2024; 9(9): 544-560.

DOI: https://doi.org/10.23857/pc.v9i9.7949

VII. Torres I, Briz A, Botella R. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020; 34: 2066-2077.

DOI: https://doi.org/10.1111/jdv.16137

VIII. Alcívar IE, Criollo LS, Córdova MK, et. al. Necrólisis epidérmica tóxica y síndrome de Steven Johnson: una revisión de su epidemiología, fisiopatología, diagnóstico y manejo. Florence: Interdisciplinary Journal of Health and Sustainability. 2024;2(2), e24004.

DOI: https://doi.org/10.56183/esq4qb25

IX. Phillips EJ, Sukasem C, Whirl M, et. al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin. Pharmacol. Ther., 2017; 103: 574-581.

DOI: https://doi.org/10.1002/cpt.1004

X. Chang HC, Wang TJ, Lin MH, Chen TJ. A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biomedicines. 2022; 10(9):2105.

DOI:https://doi.org/10.3390/biomedicines10092105